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Introduction
Diabetic retinopathy (DR) remains a leading cause of blindness in the United States (Frank, 1991; Lim and Murphy, 1971) . It is manifated by progressive changes in the eye microvasculature, with basement membrane (BM) thickening (and sometimes duplication), pericyte loss, increased vessel permeability, retinal edema, capil-lary closure, and microaneurysms, vitreous hemorrhages, retinal neovascularization, and formation of preretinal membranes that can contract and cause retinal detachments (Mandarino, 1992; Frank, 1971; @=erby, 19700; Williamson et al., 1988) .
It has long been recognized that DR manifestations, including BM thickening, n~u I a r i z a t i o n , and f o~a t~o n of preretinal membranes, involve alterations of parenchymal Wd m i c r~u i~ extracellular matrix (ECM), particularly BMs. Vascular BM thickening may result from excessive synthesis andlor reduced degradation by the endothelium activated by hyperglycemia and/or ischemia and may lead to the isolation of pericytes from endothelial cells and blood supply. This, in turn, may cause pericyte loss and release of endothelium from pericyte-mediated growth control, leading to neovascularization (D'Amore, 1994; McAvoy and Chamberlain, 1990) . Similar, hyperglycemia-induced accumulation of BM components may be responsible for parenchyma1 BM thickening in diabetes (Mandarino, 1992 ; W i l l~s o n et ai., 1988) .
It i s not clear whether DR alterations in parenchymai and vas-cular (including neovascular) BMs involve an abnormal accumulation of some specific components andlor a loss of others. A distinct layering observed by electron microscopy in at least some diabetic BMs (gsterby, 1990) suggests that the accumulated components are properly assembled. Diabetic nephropathy brings about a decrease in heparan sulfate proteoglycan and an increase in a BM chondroitin sulfate proteoglycan, Type IV collagen, and advanced glycation endproducts in glomerular capillary BMs Inoue and Bendayan, 1995; Kasinath et al., 1994; McCarthy et al., 1994; Williamson et al., 1988) . Similar information on ocular BM changes in diabetes, and especially in DR, is rather scarce. Fibronectin was previously reported to be increased in diabetic retinal BMs, without a special reference to DR (Roy et al., 1996; Kohno et al.. 1987a) . Comparisons of vascular BM composition between newly forming and mature ocular blood vessels revealed no qualitative differences (Gariano et al., 1996; Jerdan et al., 1991) , and possible BM alterations in DR neovasculature have not been studied. ECM and BM changes may be brought about by diabetesinduced alterations in angiogenic and fibrogenic growth factors. Levels of some of these factors, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGFZ), and insulin-like growth factor-I, are elevated in diabetic retina and vitreous (Aiello et al., 1994; D'Amore, 1994; Jampol et al., 1994; Malecaze et al., 1994; Sivalingam et al., 1990; . Recent evidence strongly suggests that hyperglycemia-and hypoxia-inducible VEGF may be the most important factor in diabetic ocular neovascularization (Aiello et al., 1995a,b; Pe'er et al., 1995; Pierce et al., 1995; D'hore, 19%) . Hawever, the influence ofthese factors on the regulation of ECM production in diabetic retinas remains unclear.
Together with nemularization, fibrovascular membranes that are similar to fibrotic (or scar) tissue present a serious vision threat in proliferative DR (PDR). Contraction of these membranes may cause traction retinal detachments, impairing vision in PDR eyes. The membranes often grow on the retinal surface inside the vitreous (preretinally) and are vascularized accumulations of ECM and different cell types (Walshe et al., 1992; Ohira and de Juan, 1990; Sramek et al., 1989; Nork et al., 1987; . A fibrogenic cytokine, transforming growth factor-p ('KED), has been implicated in their formation (Hagedorn et al., 1993; Weller et al., 1992) .
Abnormalities of the ECM and/or growth factors produced in the diabetic eye may play an important role in disease development. Little is known, however, about the molecular changes of individual ECM and BM components in diabetic eyes with and without retinopathy, and in nemularized areas. We hypothesized that ECM and BM alterations in diabetic eyes, especially DR eyes, were the result of abnormal deposition of specific components. To test this hypothesis, we studied the ECM and BMs of normal, diabetic, and DR eyes by immunohistochemisuy with 30 individual markers, expecting to find qualitative alterations associated with DR. Although descriptive in nature, this work is a necessary first step in identlfying ECM and BM markers of human DR for further functional and quantitative studies. We were able to find novel fibrotic alterations of the inner limiting membrane (ILM) in DR, to identify six new ECM and BM components in PDR preretinal membranes, and to document the accumulation of tenascin and Type XI1 collagen in the BM zone of newly formed blood vessels of PDR retinas and preretinal membranes. Neovascular BM changes could be correlated with VEGF expression in the same locations. The ILM and vascular BM alterations may be important in the impairment of the feedback between retina and vitreous humor that may lead to exacerbation of DR.
Materials and Methods
Tissue. Human eyes taken at autopsy were obtained from National Disease Research Interchange within 40 hr post mortem. All globes were treated in the same manner: they were frozen in liquid nitrogen vapors immediately on receipt, bisected, and embedded in OCT (Miles; Elkhart, IN). Indirect immunofluorescent staining and photography were performed as previously described . Routine specificity controls (without primary or secondary antibodies) were negative. Cryostat sections of normal and diabetic eyes were simultaneously exposed to the same dilutions of antibodies. Hybridoma supematants were used undiluted, and polyclonal antibodies were used at a concentration of 20 pglml. At least two independent experiments were performed on each eye for each marker, with identical results. No significant differences in the distribution patterns of ECM and BM components were noted among eyes in the same group, embedded between 11 and 40 hr post mortem. In the present analysis, age-matched nondiabetic eyes (n = 7). diabetic eyes without DR (n = 5; all with NIDDM), and eyes with clinically documented history of DR (n = 13; seven with IDDM including two with prior laser treatment for PDR; six with NIDDM) were included. Prior laser photocoagulation did not influence the results, except that one treated eye showed an apparent recurrence of neovasculatization of the disc. One preretinal diabetic membrane removed during pars plana vitrectomy for NIDDM PDR was also analyzed.
Antibodies. Antibodies to human al-a6 chains of Type IV collagen, to a1 (A), a2 (M), a3 (K), 01 (Bl), 02 (S), 03 (kalinin Bl), and y l (82) chains of laminin, to entactinlnidogen, to Types VII, XII, and XIV collagen, to perlecan core protein domain IV (clones A7L6 and CllI.1). to bamacan (a chondroitin sulfate BM proteoglycan), and to fibronectin (including the ED-B-containing isoform, clone BC-1) have been described previously (Couchmanet al., 1995 (Couchmanet al., ,1996 Ljubimov et al., 1995; Ninomiyaet al., 1995; Sado et al., 1995; Castellani et al., 1994; Lunstrum et al., 1991) . A monoclonal antibody to human Type VI collagen a 3 chain (clone 3C4) (Engvall et al., 1986 ) was a gift from Dr. E. Engvall (La Jolla Cancer Research Foundation, La Jolla, CA). Affinity-purified polyclonal antibodies to bovinelhuman Types I, 111, and V collagen were from Southern Biotechnology (Birmingham, AL), polyclonal antibodies to human vittonectin and decorin and monoclonal antibodies (MAbs) to human tenascin (clone TN-2). integrins a43 (clone LM609) and a& (clone PlF6) from Chemicon International (Temecula, CA), MAbs to human vimentin (clone Vim 3B4) and glial fibrillary acidic protein (clone G-A-5) from Boehringer Mannheim (Indianapolis, IN), an MAb to cellular fibronectin (clone IST-9) from Sera-Lab (Crawley Down, UK), an MAb to bovinelhuman Type VI11 collagen a1 chain (clone 9H3) from Seikagaku America (Rockville, MD), a mixture of MAbs to human keratins (pankeratin cocktail), polyclonal antibodies to human von Willebrand factor and an MAb to human a-smooth muscle actin (clone 1A4) from Sigma Chemical (St Louis, MO), polyclonal antibodies to human VEGF from Santa Cruz Biotechnology (Santa CNZ, CA), and an MAb to chicklhuman Type I1 collagen (clone 11-II6B3) was from Developmental Studies Hybridoma Bank. Cross-species-adsorbed fluorescein-and rhodamine-conjugated secondary antibodies were from Chemicon International.
Statistical Analysis. This was performed using a two-sided Fisher's exact test. 
Results
The organization of normal ocular ECM and BMs and their alterations in human diabetic and DR eyes are described below. In performing immunofluorescence analysis of these eyes, we focused on regions usually affected by diabetes: cornea, iris, ciliary body, and retina (Figure 1 ).
Cornea
The distribution of stromal ECM and BM components in corneas of non-DR diabetic eyes was similar to that of normal eyes. Some DR corneas, however, unlike normal ones, displayed weak and discontinuous staining of the central epithelial BM for chains of laminin-l (alplyl), a3-a4 chains ofType IV collagen, and entactinhidogen (Table 1 ). The distribution of other BM components. such asTypeVI1 collagen, perlecan, laminin-5 (p3 chain), and a5-a6 chains of Type IV collagen, as well as of Descemet's membrane constituents, did not change (not shown).
IriJ
In normal eyes, the BM of pigmented epithelium was previously shown to contain Types I and IV (al-a5 chains) collagen (Konstas et al.. 1990; Kleppel et al., 1989a) . We also have found in this BM zone Types 111, IV [all six a(1V) chains], V, and XIV collagen, laminin chains al. p1,82, yl (compatible with the presence of laminin-1 and laminin-2), perlecan, entactinhidogen, bamacan, and vitronectin ( Table 2) . Most of these components were also seen in blood vessel walls (Table 2 ). In addition to Types 1,111, V. and VI collagen previously seen in the iris stroma (Konstas et al.. 1990; Rittig et al., 1990) , we found perlecan, bamacan, type XI1 collagen (weak), and fibronectin (weak). In diabetic and DR eyes, the qualitative composition of the iris BMs and stromal ECM was not significantly changed compared to normals (not shown). None of the examined eyes had a clinical history of rubeosis iridis.
Ciliary Body
The nonpigmented epithelial BM in pars plana has been shown to contain al-a5 chains of Type IV collagen, laminin chains al, (32, yl (laminin-2) and Types 1 and I11 collagen (Wang et al., 1994; Marshall et al., 1992; Kleppel et al., 1989a,b) . In addition, we found perlecan, bamacan, entactinhidogen, vitronectin. Types VI and XIV collagen (weak), and the a6 chain of Type IV collagen in this BM (Table 2 ). In pars plicata, this BM also stained weakly for laminin a2 and p1 chains (not shown). The pigmented epithelial BM in pars plana, compared to the nonpigmented BM, also had the laminin D1 chain (compatible with laminin-l presence) as shown previously (Wang et al., 1994; Marshall et al., 1992; Kleppel et al., 1989a.b ). In the present study, the a2 chain of laminin and some fibronectin were also found in the pigmented epithelial BM (Table 2). In pars plicata. this BM had no detectable fibronectin (not shown). The blood vessel walls in the ciliary body stained for most markers (Table 2) . In DR eyes, ciliary body BMs often appeared thickened compared to normals, but their qualitative composition was not changed (not shown).
Retina
In this region, major alterations in BM composition were observed in DR eyes. Owing to autofluorescence of Bruch's membrane, it was difficult to assess its composition. Previously, laminin and a3-aS chains of Type IV collagen were identified in the normal ILM (Essner and Lin, 1988; Kleppel et al., 1989a,b; Kohno et al., 1987b) . The present report confirms these data on type IV collagen [adding the a6(IV) chain] and also documents for the first time laminin chains a2, p2, yl (compatible with laminin-4 presence; other tested chains were not found), Type XIV collagen, entactinhidogen, and perlecan in normal human ILM (Table 2 ). In keeping with previous results (Sarthy, 1993; Essner and Lin, 1988) , fibronectin (including cellular) and al-a2 Type IV collagen were not found in normal ILM (Figures 2a and 2c) .
In diabetic non-DR eyes, normal ILM composition was preserved.
In DR eyes, however, the ILM was usually thicker than normal and its composition was severely altered. Several ECM components were abnormally accumulated in DR ILM (Table 1) (Roy et al., 1994) .
Preretinal Membranes in PDR
In four eyes, fibrovascular preretinal membranes were seen in the vicinity of the optic nerve (one had been surgically removed and studied separately). Preretinal membrane ECM has been shown to contain Types I, 11,111, and V collagen, tenascin, decorin, thrombospondin, fibronectin, with Type iV collagen, vitronectin, and laminin in microvessel BMs (Casaroli Marano et al., 1995; Hagedoni et al., 1993; Hosoda et al., 1992; Weller et al., 1992; Immonen et al., 1991; Scheiffarth et al., 1988; . In our study, most of the above components and, in addition, perlecan, bamacan, Types VI, VIII, XII, and XIV collagen were found in preretinal membranes (Figures 3a and 4 ; Table 1 ). In some blood vessel walls, VEGF was found (Figure 3c ), suggesting its role in vessel development within the membranes. VEGF immunoreactivity was found elsewhere only in neovascularized retinal areas (see below). In preretinal membranes, we observed myofibroblasts positive for vimentin and a-smooth muscle actin (Figure 3d ), glial cells containing glial fibrillary acidic protein, and epithelial cells (presumably retinal pigment epithelium; see Vinores et al., 1992 ) positive for keratin (not shown).
Neovascdarization in PDR
The composition of normal retinal blood vessel BMs has been studied previously (Gariano et al., 1996; Das et al., 1990b; Kleppel et al., 1989a; Essner and Lin, 1988; . To the list of components found in retinal vascular BM zone, we added laminin chains al, a2, fil, p2, yl (compatible with the presence of laminins 1-4), entactinhidogen, and Types VI and XN collagen (Table 2) . Staining for chains of laminins 5-7 (a3 and B3) was negative. In non-DR diabetic retinas, vessel BM composition was similar to normal. Even in DR eyes without neovaxularization, the qualitative composition of the retinal blood vessel BMs did not change, although vessels with sclerosed laminated walls were more common compared to normals. An area of neovaxularization (apparently a recurrence after laser treatment) was found close to the optic disc of a PDR eye. New blood vessels of three PDR preretinal membranes were also studied, with identical results. In the nemcularized area, many small vessels were seen in the retina close to the ILM (Figure 5a ), and at least some of them were positive for VEGF ( Figure 5b) . The BM zone of many of the new blood vessels was positive for an oncofetal fibronectin isoform containing the ED-B domain, a marker of angiogenesis (Castellani et al., 1994) . Only weak and irregular staining for this isoform was occasionally seen elsewhere (not shown).
In addition, the BM zone of new vessels stained strongly for Type XI1 collagen and tenaxin (Figures 5d, bc ; Table 1 ). The same was true for new vessels of preretinal membranes (Figures 3a. 3b, and  4e) . In retinal areas adjacent to the neovascularization zone, only weak staining of vessel walls was observed for Type XI1 collagen and tenascin (Figures 5c and 6a) . New blood vessels were positive for the a& vitronectin-binding integrin (Figure 7b) but not for the a& integrin (Figure 7d ). New vessels stained more strongly for a6(IV) chain, fibronectin (including cellular), and Type VI11 collagen than vessels in non-neovascularized areas (not shown).
Discussion
In the present study we tried to determine whether the well-known diabetic thickening of ocular BMs was associated with qualitative changes in the distribution of BM components in several eye regions, i.e., cornea, ciliary body, iris, and retina. Diabetes without DR did not involve qualitative BM alterations in any of these regions. Only in advanced disease with DR were qualitative changes observed in cornea and retina.
In the cornea, weak and discontinuous staining of the epithelial BM for laminin-1 chains, entactinhidogen, and a3-a4 Type IV collagen chains was observed in some DR cases. These alterations are consistent with poor adhesion of corneal epithelium and abnormal epithelial-stromal interactions in diabetic corneas (Azar et al., 1992) .
In the ciliary body and the iris, even DR eyes did not show qualitative BM changes compared to normal eyes. It appears that diabetic thickening of iris and ciliary body BMs is due to quantitative rather than qualitative alterations. A detailed study of BM composition in the ciliary body enabled us to identify its regional heterogeneity. The nonpigmented epithelial BM in ciliary body pars plicata had more laminin isoforms than in pars plana ( Table 2) . This is one of the rare examples of a regional heterogeneity in a BM underlying the same continuous epithelial layer (another one is the renal tubule BM). This result cannot be explained by a different origin of BM-producing cells, a common reason for BM heterogeneity in tissues Yurchenco and O'Rear, 1994) . Because pars plicata experiences more mechanical stress and tension than pars plana, the aqueous humor-facing nonpigmented epithelium may need stronger adhesion to its BM there than in pars plana. Additional laminin isoforms may mediate this increased adhesion.
In the retina, major DR-associated changes were found primarily in the ILM (Table 1 ). ILM is the Muller cell BM located at the vitreoretinal border (Heegard. 1994) . separating the retina from the vitreous humor. Electron microscopy has demonstrated 10-25nm pores in this structure (Nishihara, 1989) . which is not typical for a BM. These pores may play a role in the barrier and/or filtration function of the ILM. The composition of ILM was. however, rather typical for a BM. The only unusual thing about it was the pattern of laminin chains compatible with the presence of laminin-4, an isoform reported only in trophoblast BM, synaptic portions of muscle BM (Engvall, 1993) . and the limba1 and conjunctival BM . Previously, laminin p2 chain was found in developing retina (Libby et al., 1996) but no expression of a widespread laminin 81 chain was revealed in Muller glia (Sarthy and Fu, 1990) . These results are in keeping with our data showing the presence of a rare, 82 chain-containing, laminin-4 isoform in the ILM deposited by Muller cells. Its functional significance in the ILM remains unknown. With the recent discovery of several new laminin chains (Engvall and Wewer, 1996) . it is possible that other laminin variants may be also present in the ILM.
No qualitative retinal ECM and BM changes detectable by immunohistochemistry were observed in non-DR retinas. In contrast, in DR retinas, consistent fibrotic changes of the ILM were found. These were manifested by a significant abnormal deposition of fibronectin and of Types I. 111, . and V collagen ( Figure  2 ; Table 1 ). The appearance of cellular fibronectin in the DR ILM suggests that fibronectin accumulation was not due to trapping from plasma. We confirmed previous data on the upregulation of fibronectin in diabetic ILM (Kohno et al.. 1987a ; presence or absence of DR was not specified). Contrary to the cited report (Kohno et al., 1987a) . however, we found no apparent changes of laminin in the DR ILM compared to normal ILM. This might be due to differences in the antibody specificity or the disease stage.
The mechanism of fibrotic alterations of the ILM in DR is not known. One can suggest that they may result from abnormal synthetic activity of Muller cells normally forming ILM. brought about by diabetes-induced upregulation of cytokines, such as VEGF. It would be important to study the effects of VEGF and hyperglycemialischemia on the ECM production by cultured Muller cells. The elucidation of possible structural changes to the ILM in DR as a result of fibrosis, particularly with respect to the ILM pores, would be also of interest. Normal vitreous humor contains angiogenesis inhibitors (Banerjee et al., 1992) that may prevent retinal neovascularization. In DR, an accumulation of collagens and fibronectin in the ILM, a vitreoretinal barrier, may prevent the access of these vitreal factors to the retinal vessels through the ILM pores. These fibrotic ILM alterations could result in an abnormal interaction between retina and vitreous by limiting access of retinal cells to vitreal growth inhibitors, leading to angiogenesis and further preretinal fibrosis.
A very complex ECM was found in diabetic preretinal membranes in PDR. We have newly identified six components in this ECM (Table 1) . At least three cell types, myofibroblasts. glial cells, and epithelial cells, were found in these membranes. Glial cells (Muller cells andlor astrocytes) and myofibroblasts are frequently found in such membranes. They may be important for membrane contraction (Walshe et al., 1992; Ohira and de Juan, 1990; Sramek et al.. 1989; . which is the cause of visionimpairing traction retinal detachments. The presence of such diverse cell types might explain the complexity of the preretinal membrane ECM, which is a mixture of interstitial and BM components.
Retinal neovascularization is a major vision threat in PDR, but the associated molecular changes of the microvessel BMs remain obscure. In thickened retinal vessel BMs of galactosemic rats, an accumulation of laminin and Type IV collagen was demonstrated by immunoelectron microscopy (Das et al., 1990a) . However. the appearance of some abnormal fibrils in these BMs was attributed to the accumulation of Types I and 111 collagen, which are found in the BM zone of normal retinal vessels. In this report, no qualitative changes in composition of mature retinal vessel BMs could be associated with diabetes or with DR. The qualitative nature of immunofluorescence did not allow us to reveal minor quantitative changes. Such changes could be of importance, because the laminin-entactin complex in vitro can stimulate or inhibit angiogenesis, depending on its concentration (Nicosia et al.. 1994) . However. our method was sensitive enough to reveal an accumulation of tenascin and Type XI1 collagen in the new blood vessel BM zone of PDR retinas and preretinal membranes (Figures 3a, 4e, 5d . and 6c; Table l). Selective accumulation of tenascin and Type XI1 collagen in the neovascular BM zone could be related to PDR-associated changes in the ECM receptor (integrin) pattern in neovascular endothelium (Robbins et al., 1994) . The expression of angiogenesisrelated vitronectin-binding integrin in new retinal vessels in PDR (Figures 7a and 7b ) could contribute to their abnormal growth. Surprisingly, in PDR neovasculature, no staining was seen for a related integrin. avS3 (Figures 7c and 7d) , usually implicated in vessel growth (Brooks et al., 1994) . PDR may therefore be different from other situations associated with angiogenesis.
Alterations of BM composition in diabetic retinal neovasculature may render the vessel walls more fragile and prone to leakage, and thus may lead to retinal hemorrhages. Pericyte dropout earlier in the course of diabetes might contribute to BM changes in retinal neovasculature. as suggested from tissue culture studies (Mandarino et al., 1993) . Anti-adhesive tenascin might further inhibit pericyte association with new diabetic retinal vessels, contributing to abnormalities of their structure and function. Because tenascin can also stimulate the acquisition of sprouting phenotype by cultured endothelial cells (Canfield and Schor. 1995) . it might promote diabetic neovascularization in vivo.
The first evidence of qualitative PDR-associated changes in newly formed retinal blood wssel BM zone composition is presented here.
Previously, BM compositions of newly forming and mature vessels were found qualitatively similar to each other in the rodent model of corneal neovascularization ( Jerdan et al., 1991) and in monkey retinal development (Gariano et al., 1996) . It should be noted that tenascin and Type XI1 collagen were not included in those studies.
However, tenascin in some tumors appears to be associated with neovascularization (Zagzag et al., 1995) , which is in keeping with data reported here.
The influence of angiogenic and fibrogenic cytokines on Type XI1 collagen expression has not been studied. Tenascin expression can be induced or upregulated by several cytokines, such as FGFZ and EFf31 (Chiquet-Ehrismann, 1995) . Our data and data in the literature show that in PDR retinas with neovascularization, VEGF is specifically upregulated (Figures 3c and 5b ) (see also Pe'er et al., 1995; Aiello et al., 1994 Aiello et al., ,1995b Malecaze et al., 1994) . Therefore, one can speculate that VEGF could upregulate tenascin and Type XI1 collagen in microvascular cells. If this hypothesis is correct, it would be interesting to find out which form of Type XI1 collagen (long or short; see Watt et al., 1992) and which tenascin splice variants (see Chiquet-Ehrismann, 1995) would be affected. Studies in this area are under way.
The present study has provided the first information on ECM and BM markers qualitatively altered in DR. In non-DR diabetic eyes, ECM and BM were qualitatively similar to normal eyes, suggesting that a long-known diabetic BM thickening may involve quantitative changes. In more severe diabetes with DR, only in cornea and especially in retina was BM composition qualitatively altered.
In some DR corneas, reduced staining of the epithelial BM for major components was noted. In most DR retinas, ILM was abnormal, with fibrotic deposition of fibronectin and of Types I, III, IV (al-az), and V collagen. Fibrotic accumulation of ECM was also found in PDR preretinal membranes and in new blood vessel BM zone in neovascularized areas (tenascin and Type XI1 collagen upregulation). The observed BM alterations may be caused by hyperglycemialischemia and/or by abnormally expressed growth factors, such as VEGF. The ILM and vessel BM changes could lead to impaired feedback between retina and vitreous which, in tum, may be important for the development of endstage PDR. Now that we have identified specific BM markers qualitatively changed in DR, we can proceed with studies of specific growth factors (especially VEGF) as possible triggers for the upregulation ofthese markers in human DR.
